Arbutus Biopharma Corp (ABUS) Return on equity 2016–2025
Arbutus Biopharma Corp (ABUS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-43.7%FY2025 · since FY2016: -189.2% → -43.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -43.7% | +28.1 pp |
| FY2024 | -71.8% | -3.1 pp |
| FY2023 | -68.7% | -18.0 pp |
| FY2022 | -50.8% | -5.8 pp |
| FY2021 | -45.0% | +17.5 pp |
| FY2020 | -62.5% | +148.8 pp |
| FY2019 | -211.3% | -182.8 pp |
| FY2018 | -28.5% | +17.8 pp |
| FY2017 | -46.3% | +143.0 pp |
| FY2016 | -189.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Net marginABUS Gross profitABUS Gross marginABUS Operating incomeABUS Operating marginABUS Operating cash flowABUS Free cash flowABUS Capital expendituresABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Total liabilitiesABUS Shareholders’ equityABUS overview →